The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

Immune checkpoint inhibitors cause side effects ranging from autoimmune endocrine
disorders to severe cardiotoxicity. Periodic Fasting mimicking diet (FMD) cycles are …

Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 …

Checkpoint inhibitor-based cancer immunotherapy is often combined in the clinic with other
immunotherapy strategies, targeted therapies, chemotherapy or standard-of-care treatments …

The majority of the well-known pharmacogenomics research used in the medical sciences
contributes to our understanding of medication interactions. It has a significant impact on …

Cancer immunotherapy with immune-checkpoint blockade has improved the outcomes of
patients with various malignancies, yet a majority do not benefit or develop resistance. To …

Regulatory T cells (Tregs) are among the most abundant suppressive cells, which infiltrate
and accumulate in the tumor microenvironment, leading to tumor escape by inducing anergy …